ArticleMedComm2025

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors.

Zihong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.